Taj Pharmaceuticals as Manufacturer of Dopamine Hydrochloride Injection USP 200mg/5ml Dopamine Hydrochloride Injection USP 200mg/5ml manufacturer in India {Taj Pharmaceuticals}; best quality supplier and exporter of Dopamine Hydrochloride Injection USP 200mg/5ml Taj Pharmaceuticals manufactures a wide range of pharmaceuticals formulation involving Tablets / Capsules / Injections and Orals. Taj Pharma India team has an excellent expertise in manufacturing and export of Dopamine Hydrochloride Injection USP 200mg/5ml. Taj Pharmaceuticals places its main business as a Pharmaceuticals manufacturing and exports of generic drug supply of Dopamine Hydrochloride Injection USP 200mg/5ml; primarily of pharmaceuticals preparations known as Dopamine Hydrochloride Injection USP 200mg/5ml; as well as more than 100+ generic equivalent drug. Taj Pharmaceuticals has performed these business activities related to exports of Dopamine Hydrochloride Injection USP 200mg/5ml for major foreign-affiliated pharmaceutical import companies, ministry of health, tenders etc. and have enjoyed the full confidence of these companies, instructions and governments. Taj Pharma Group Under close cooperation between the formulation manufacturing division, active ingredient division and the technology development division for major generic formulations such as Dopamine Hydrochloride Injection USP 200mg/5ml; at Taj Pharma we will appropriately meet diverse needs for Dopamine Hydrochloride Injection USP 200mg/5ml export manufacturing in a wide range of activities from investigation of possible formulations of Dopamine Hydrochloride Injection USP 200mg/5ml, formulation development, making applications to the international regulatory authorities for marketing approval, validation of Dopamine Hydrochloride Injection USP 200mg/5ml through to manufacturing scale production at our cGMP compliant manufacturing units of Taj Pharmaceuticals under the umbrella of Taj Pharma Group. We at Taj Pharma intend to make our manufacturing systems comply with the requirements of the FDA (cGMP) such that pilot plant scale production of products in the stage of clinical development or for use in clinical studies, as well as manufacture of products in small lots are practicable to ensure a highly stable pharmaceuticals formulations of generic equivalent and bio-similar products. We conduct extensive bio-similar and bio-equivalency studies for all our formations